LeHavreV1, France, Analysis, bibRecord, 001197

Frequency and cost of serious adverse drug reactions in a department of general medicine

Identifieur interne : 001197 ( France/Analysis ); précédent : 001196; suivant : 001198

Frequency and cost of serious adverse drug reactions in a department of general medicine

Auteurs : Nicholas Moore [France] ; Dominique Lecointre [France] ; Catherine Noblet [France] ; Michel Mabille [France]

Source :

British Journal of Clinical Pharmacology [ 0306-5251 ] ; 1998.

RBID : PMC:1873369

Abstract

Aims

To assess the frequency and cost of drug reactions causing or prolonging hospitalization.

Methods

All patients admitted to an internal medicine ward over 6 months were evaluated to identify serious adverse reactions. The number of drug classes on admission or at the time of the adverse drug reaction (ADR) was counted. Excess ADR-related hospital stay was computed using a) raw excess duration of hospital stay, b) correction of duration of hospital stay by age, sex, and number of drug classes, and c) estimation by investigator of excess hospital stay.

Results

Three hundred and twenty-nine patients were evaluated: 212 male, 117 female, mean age 57.2 (males: 52.2, females: 66.2 (P< 0.05)), range 17–95 years. They stayed a total of 3720 hospital days (mean stay 11.3 days). 298 had no ADR (mean age 55.8, taking a mean of 2.7 drug classes, 10.7 days hospital stay); 31 had ADRs: in 10, the ADR caused admission in patients with a mean age of 84 (P< 0.01 vs the two other groups), taking 6.3 drug classes, who stayed a mean of 15.1 days; 21 occurred in hospital in patients with a mean age of 63.6, taking 4.2 drug classes (P< 0.01), who stayed a mean of 19.2 days (P< 0.01 vs patients without ADRs). In four the ADR was fatal (13% of ADRs, 40% of deaths). Raw ADR-related excess hospital stay was 318 days (8.6% of all hospital days), after multivariate correction 282 days (7.6% of all hospital days), and with investigator estimation 197 days (5.3% of all hospital days). Point prevalence of ADRs at admission was 3%, incidence rate in hospital was 5.6/1000 patient-days.

Conclusions

3% of the admissions were related to ADRs. In addition, 6.6% of hospitalized patients had significant ADRs. Between 5 and 9% of hospital costs were related to ADRs. In 24 of the 31 patients with ADRs (77%), these were related to the pharmacological properties of the involved drugs, and may possibly have been avoidable.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1873369

DOI: 10.1046/j.1365-2125.1998.00667.x
PubMed: 9517375
PubMed Central: 1873369

Affiliations:

France

Links to Exploration step

PMC:1873369

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Frequency and cost of serious adverse drug reactions in a department of general medicine</title>
<author><name sortKey="Moore, Nicholas" sort="Moore, Nicholas" uniqKey="Moore N" first="Nicholas" last="Moore">Nicholas Moore</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Pharmacology, Université V. SEGALEN, CHU de Bordeaux</institution>
<addr-line>33076 Bordeaux Cedex, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>33076 Bordeaux Cedex</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lecointre, Dominique" sort="Lecointre, Dominique" uniqKey="Lecointre D" first="Dominique" last="Lecointre">Dominique Lecointre</name>
<affiliation wicri:level="1"><nlm:aff id="au3"><institution>Service de Médecine Interne, CHG du Havre</institution>
<addr-line>76100 Le Havre, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>76100 Le Havre</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Noblet, Catherine" sort="Noblet, Catherine" uniqKey="Noblet C" first="Catherine" last="Noblet">Catherine Noblet</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Department of Pharmacology, CHU de Rouen</institution>
<addr-line>76031 Rouen Cedex, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>76031 Rouen Cedex</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mabille, Michel" sort="Mabille, Michel" uniqKey="Mabille M" first="Michel" last="Mabille">Michel Mabille</name>
<affiliation wicri:level="1"><nlm:aff id="au3"><institution>Service de Médecine Interne, CHG du Havre</institution>
<addr-line>76100 Le Havre, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>76100 Le Havre</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">9517375</idno>
<idno type="pmc">1873369</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1873369</idno>
<idno type="RBID">PMC:1873369</idno>
<idno type="doi">10.1046/j.1365-2125.1998.00667.x</idno>
<date when="1998">1998</date>
<idno type="wicri:Area/Pmc/Corpus">000181</idno>
<idno type="wicri:Area/Pmc/Curation">000179</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000158</idno>
<idno type="wicri:Area/Ncbi/Merge">000621</idno>
<idno type="wicri:Area/Ncbi/Curation">000621</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000621</idno>
<idno type="wicri:doubleKey">0306-5251:1998:Moore N:frequency:and:cost</idno>
<idno type="wicri:Area/Main/Merge">001C07</idno>
<idno type="wicri:Area/Main/Curation">001B57</idno>
<idno type="wicri:Area/Main/Exploration">001B57</idno>
<idno type="wicri:Area/France/Extraction">001197</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Frequency and cost of serious adverse drug reactions in a department of general medicine</title>
<author><name sortKey="Moore, Nicholas" sort="Moore, Nicholas" uniqKey="Moore N" first="Nicholas" last="Moore">Nicholas Moore</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Pharmacology, Université V. SEGALEN, CHU de Bordeaux</institution>
<addr-line>33076 Bordeaux Cedex, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>33076 Bordeaux Cedex</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lecointre, Dominique" sort="Lecointre, Dominique" uniqKey="Lecointre D" first="Dominique" last="Lecointre">Dominique Lecointre</name>
<affiliation wicri:level="1"><nlm:aff id="au3"><institution>Service de Médecine Interne, CHG du Havre</institution>
<addr-line>76100 Le Havre, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>76100 Le Havre</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Noblet, Catherine" sort="Noblet, Catherine" uniqKey="Noblet C" first="Catherine" last="Noblet">Catherine Noblet</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Department of Pharmacology, CHU de Rouen</institution>
<addr-line>76031 Rouen Cedex, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>76031 Rouen Cedex</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mabille, Michel" sort="Mabille, Michel" uniqKey="Mabille M" first="Michel" last="Mabille">Michel Mabille</name>
<affiliation wicri:level="1"><nlm:aff id="au3"><institution>Service de Médecine Interne, CHG du Havre</institution>
<addr-line>76100 Le Havre, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>76100 Le Havre</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">British Journal of Clinical Pharmacology</title>
<idno type="ISSN">0306-5251</idno>
<idno type="eISSN">1365-2125</idno>
<imprint><date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Aims</title>
<p>To assess the frequency and cost of drug reactions causing or prolonging hospitalization.</p>
</sec>
<sec sec-type="methods"><title>Methods</title>
<p>All patients admitted to an internal medicine ward over 6 months were evaluated to identify serious adverse reactions. The number of drug classes on admission or at the time of the adverse drug reaction (ADR) was counted. Excess ADR-related hospital stay was computed using a) raw excess duration of hospital stay, b) correction of duration of hospital stay by age, sex, and number of drug classes, and c) estimation by investigator of excess hospital stay.</p>
</sec>
<sec><title>Results</title>
<p>Three hundred and twenty-nine patients were evaluated: 212 male, 117 female, mean age 57.2 (males: 52.2, females: 66.2 (<italic>P</italic>
< 0.05)), range 17–95 years. They stayed a total of 3720 hospital days (mean stay 11.3 days). 298 had no ADR (mean age 55.8, taking a mean of 2.7 drug classes, 10.7 days hospital stay); 31 had ADRs: in 10, the ADR caused admission in patients with a mean age of 84 (<italic>P</italic>
< 0.01 <italic>vs</italic>
 the two other groups), taking 6.3 drug classes, who stayed a mean of 15.1 days; 21 occurred in hospital in patients with a mean age of 63.6, taking 4.2 drug classes (<italic>P</italic>
< 0.01), who stayed a mean of 19.2 days (<italic>P</italic>
< 0.01 <italic>vs</italic>
 patients without ADRs). In four the ADR was fatal (13% of ADRs, 40% of deaths). Raw ADR-related excess hospital stay was 318 days (8.6% of all hospital days), after multivariate correction 282 days (7.6% of all hospital days), and with investigator estimation 197 days (5.3% of all hospital days). Point prevalence of ADRs at admission was 3%, incidence rate in hospital was 5.6/1000 patient-days.</p>
</sec>
<sec><title>Conclusions</title>
<p>3% of the admissions were related to ADRs. In addition, 6.6% of hospitalized patients had significant ADRs. Between 5 and 9% of hospital costs were related to ADRs. In 24 of the 31 patients with ADRs (77%), these were related to the pharmacological properties of the involved drugs, and may possibly have been avoidable.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
</list>
<tree><country name="France"><noRegion><name sortKey="Moore, Nicholas" sort="Moore, Nicholas" uniqKey="Moore N" first="Nicholas" last="Moore">Nicholas Moore</name>
</noRegion>
<name sortKey="Lecointre, Dominique" sort="Lecointre, Dominique" uniqKey="Lecointre D" first="Dominique" last="Lecointre">Dominique Lecointre</name>
<name sortKey="Mabille, Michel" sort="Mabille, Michel" uniqKey="Mabille M" first="Michel" last="Mabille">Michel Mabille</name>
<name sortKey="Noblet, Catherine" sort="Noblet, Catherine" uniqKey="Noblet C" first="Catherine" last="Noblet">Catherine Noblet</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001197 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 001197 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/France
   |area=    LeHavreV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     PMC:1873369
   |texte=   Frequency and cost of serious adverse drug reactions in a department of general medicine
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i   -Sk "pubmed:9517375" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a LeHavreV1

This area was generated with Dilib version V0.6.25.
Data generation: Sat Dec 3 14:37:02 2016. Site generation: Tue Mar 5 08:25:07 2024

Serveur d'exploration sur la visibilité du Havre

Frequency and cost of serious adverse drug reactions in a department of general medicine

Frequency and cost of serious adverse drug reactions in a department of general medicine

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur la visibilité du Havre
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.